COPD Insights for Primary Care: 5 New Studies

Slideshow

Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.

Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Telehealth in Pediatric Primary Care Linked to Lower Antibiotic Prescribing for Respiratory Infections

Telehealth in Pediatric Primary Care Linked to Lower Antibiotic Prescribing for Respiratory Infections

Sydney Jennings
April 29th 2025
Article

Telehealth visits in pediatric primary care were linked to lower antibiotic prescribing rates for respiratory infections compared with in-person visits.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates / image credit ©Kateryna_Kon/stock.adobe.com

Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates

Grace Halsey
April 2nd 2025
Article

A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

Sydney Jennings
March 24th 2025
Article

Your daily dose of the clinical news you may have missed.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose

Sydney Jennings
March 20th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.